Kenneth L Pinkston

Title: Kenneth L Pinkston: Innovator in Cancer Detection

Introduction

Kenneth L Pinkston is a notable inventor based in Houston, TX (US). He has made significant contributions to the field of cancer detection through his innovative work on monoclonal antibodies. His research focuses on improving the accuracy of cancer diagnostics, particularly in prostate cancer.

Latest Patents

Kenneth L Pinkston holds a patent for "Monoclonal antibodies targeting EpCAM for detection of prostate cancer lymph node metastases." This invention provides high affinity recombinant EpCAM-binding antibodies. The methods of using such antibodies as imaging agents, diagnostics, and therapeutics are also included. The dual-nuclear and fluorescently labeled or singly fluorescently labeled contrast agents promise the advantage of molecularly-guided surgical resection via surgical field near-infrared fluorescence (NIRF) imaging. This follows nuclear imaging for general localization, which is crucial for effective cancer treatment.

Career Highlights

Kenneth is affiliated with The University of Texas System, where he continues to advance his research in cancer detection technologies. His work is pivotal in enhancing the methods used for nodal staging of cancers, which traditionally involves lymph node biopsy and dissection for subsequent pathological examination.

Collaborations

He has collaborated with esteemed colleagues such as Eva M Sevick-Muraca and Ali Azhdarina, contributing to the advancement of cancer research and diagnostics.

Conclusion

Kenneth L Pinkston's innovative work in monoclonal antibodies represents a significant advancement in cancer detection and treatment methodologies. His contributions are vital for improving patient outcomes in cancer care.